Investor Presentaiton slide image

Investor Presentaiton

Targeted Protein Degradation offers the promise of novel targets and clinical differentiation for existing targets Expanded universe of targets (e.g., scaffolding proteins, transcription factors) Drugged: Target with approved drugs (3%) "Dark Druggable: No approved drugs, but bind small molecules with high potency (8%) Small molecule enzyme inhibitor 659 Genome": (3%) 1,607 No known (8%) 6,007 disease (30%) association (30%) Human protein - Coding genes ~20,000 Disease- relevant: No known potent binders, but implicated in disease (61%) Scaffold 12,139 (61%) Opportunity for TPD Scaffold protein Ill Bristol Myers Squibbâ„¢ COAS Transcription factor Not for Product Promotional Use 31
View entire presentation